NCT00103558已完成1 期
A Phase I/II Study of Lumiliximab in Combination With Fludarabine, Cyclophosphamide, and Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Biogen
- 入组人数
- 31
- 试验地点
- 5
- 主要终点
- Characterize the safety profile
研究概览
简要总结
This is an open label, Phase I/II, dose escalation research study of an investigational product called lumiliximab, given with FDA (Food and Drug Administration) approved products fludarabine, cyclophosphamide, and rituximab (FCR). The study duration is 17 visits over 42 months or until your disease progresses and you require additional CLL therapy. The total duration of participation in the study will be approximately 4 years, however your disease status will be followed indefinitely (forever).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age: 18 years and older
- •Diagnosis of B-cell CLL by International Workshop on CLL (IWCLL) response criteria
- •Relapsed CD23+ B-cell CLL
- •Rai Stage III or IV, or Rai Stage I or II if determined to have disease progression as evidenced by rapid doubling or peripheral lymphocyte count, progressive lymphadenopathy, progressive splenomegaly, or B symptoms
- •Prestudy WHO Performance Status less than or equal to 2
- •Signed, written Institutional Review Board (IRB)-approved informed consent
- •Men & women of reproductive potential must agree to follow accepted birth control methods during treatment for 3 months after completion of treatment
- •Acceptable liver function: Bilirubin less than or equal to 2.0 mg/dL (26 µmol/L), AST (SGOT) &/or ALT (SGPT) less than or equal to 2 times upper limit of normal
- •Acceptable hematologic status: Platelet count less than or equal to 50 x 10^9/L, ANC less than or equal to 1 x 109/L
- •Acceptable renal function: Serum creatinine less than or equal to 1.5 times upper limit of normal
排除标准
- •Subjects who did not respond to prior FCR therapy (relapsed within 6 months of the last dose).
- •Cancer radiotherapy, radioimmunotherapy, biological therapy, chemotherapy, or other investigational therapy within 4 weeks prior to Study Day 1
- •Previous exposure to lumiliximab or other anti-CD23 antibodies
- •Subjects who have had a prior allogenic bone marrow transplant (BMT) or autologous BMT or peripheral stem-cell transplant (PBSCT)
- •Known infection with HIV, hepatitis B, or hepatitis C
- •Uncontrolled diabetes mellitus
- •Uncontrolled hypertension
- •Transformation to aggressive B-cell malignancy (e.g., larger B-cell lymphoma, Richter's Syndrome, or prolymphocyte leukemia (PLL)
- •Subjects with secondary malignancy requiring active treatment (except hormonal therapy)
- •Subjects with medical conditions currently requiring long-term use (less than 1 month) of systemic corticosteroids
- •Serious nonmalignant disease or laboratory abnormality, which, in the opinion of the investigator &/or sponsor, would compromise protocol objectives
- •Active uncontrolled bacteria, viral, or fungal infections
- •New York Heart Association Class III or IV cardiac disease, myocardial infarction within the past 6 months prior to Study Day 1, unstable arrhythmia, or evidence of ischemia on ECG within 14 days prior to Study Day 1
- •Seizure disorders requiring anticonvulsant therapy
- •Severe chronic obstructive pulmonary disease with hypoxemia
- •Major surgery, other than diagnostic surgery, within 4 weeks prior to Study Day 1
- •Clinically active autoimmune disease
- •Subjects with a history of fludarabine-induced autoimmune cytopenia
- •Pregnant or currently breast-feeding
结局指标
主要结局
Characterize the safety profile
时间窗: monthly until month 12, then every 3 months for 24 months, then every 6 months until month 48
次要结局
- Evaluate the pharmacokinetics of lumiliximab and rituximab(6 months)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
1 期
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung CancerLung CancerSCLCNCT03575793Salma Sabbour39
暂停
1 期
A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid TumorAdvanced Solid TumorGynecologic CancerNCT04042116Clovis Oncology, Inc.227
已完成
2 期
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the BrainNCT03873818M.D. Anderson Cancer Center24
终止
2 期
Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular LymphomaSmall Lymphocytic LymphomaFollicular LymphomaNCT03828448TG Therapeutics, Inc.34
进行中（未招募）
1 期
A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal CancerNCT05609370BeiGene113